A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy ; volume:7 ; number:3 ; day:16 ; month:3 ; year:2023 ; pages:405-416 ; date:5.2023
PharmacoEconomics - open ; 7, Heft 3 (16.3.2023), 405-416, 5.2023
- Urheber
-
Cortesi, Paolo Angelo
Fornari, Carla
Gisondi, Paolo
Iannone, Florenzo
Antonazzo, Ippazio Cosimo
Aloisi, Elisabetta
Fiocchi, Martina
Ritrovato, Daniela
Mantovani, Lorenzo Giovanni
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s41669-023-00404-3
- URN
-
urn:nbn:de:101:1-2023090708552596434231
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cortesi, Paolo Angelo
- Fornari, Carla
- Gisondi, Paolo
- Iannone, Florenzo
- Antonazzo, Ippazio Cosimo
- Aloisi, Elisabetta
- Fiocchi, Martina
- Ritrovato, Daniela
- Mantovani, Lorenzo Giovanni
- SpringerLink (Online service)
Ähnliche Objekte (12)
Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab: A Review in Psoriatic Arthritis
Correction to: Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab: A New Treatment Option for Psoriatic Arthritis
Correction to: Secukinumab: A Review in Psoriatic Arthritis
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
Secukinumab (nicht röntgenologische axiale Spondyloarthritis) : Nutzenbewertung gemäß § 35a SGB V
Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort
Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab
Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
A Review of the Use of Secukinumab for Psoriatic Arthritis
IL-17 producing mast cells contribute to synovial inflammation in non-psoriatic and psoriatic spondyloarthritis
Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab: A Review in Psoriatic Arthritis
Correction to: Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab: A New Treatment Option for Psoriatic Arthritis
Correction to: Secukinumab: A Review in Psoriatic Arthritis
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
Secukinumab (nicht röntgenologische axiale Spondyloarthritis) : Nutzenbewertung gemäß § 35a SGB V
Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort
Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab
Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
A Review of the Use of Secukinumab for Psoriatic Arthritis
IL-17 producing mast cells contribute to synovial inflammation in non-psoriatic and psoriatic spondyloarthritis
Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab: A Review in Psoriatic Arthritis
Correction to: Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab: A New Treatment Option for Psoriatic Arthritis
Correction to: Secukinumab: A Review in Psoriatic Arthritis
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
Secukinumab (nicht röntgenologische axiale Spondyloarthritis) : Nutzenbewertung gemäß § 35a SGB V
Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort
Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab
Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
A Review of the Use of Secukinumab for Psoriatic Arthritis